Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias

Retrovirology

Volumn 3, Issue , 2006, Pages

  Jeeninga, Rienk E ^a   Jan, Barbara ^a   van den Berg, Henk ^b   Berkhout, Ben ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; DOXYCYCLINE; NEF PROTEIN; TRANSACTIVATOR PROTEIN; VIF PROTEIN; VIRUS VECTOR; VPR PROTEIN; VPU PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; GENE CONSTRUCT; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LEUKEMIA; MYELOID LEUKEMIA; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE; TRANSCRIPTION INITIATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CULTURE; VIRUS REPLICATION; VIRUS STRAIN;

ANTI-BACTERIAL AGENTS; ANTIGENS, CD4; CELL LINE, TUMOR; DOXYCYCLINE; GENE DELETION; GENE PRODUCTS, TAT; GENES, VIRAL; HIV-1; HUMANS; LEUKEMIA; LEUKOCYTES, MONONUCLEAR; RECEPTORS, CXCR4; T-LYMPHOCYTES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

ESCHERICHIA; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33749601616     PISSN: 17424690     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-3-64     Document Type: Article

References (44)

1. Ring CJ: Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002, 83:491-502.
2. Parato KA, Senger D, Forsyth PA, Bell JC: Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005, 5:965-976.
3. Lin E, Nemunaitis J: Oncolytic viral therapies. Cancer Gene Ther 2004, 11:643-664.
4. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274:373-376.
5. Nemunaitis J, Cunningham C, Tong AW, Post L, Netto G, Paulson AS, Rich D, Blackburn A, Sands B, Gibson B, Randlev B, Freeman S: Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther 2003, 10:341-352.
6. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, 015 an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000, 60:6359-6366.
7. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000, 6:879-885.
8. Dix BR, Edwards SJ, Braithwaite AW: Does the antitumor adenovirus ONYX-015/d11520 selectively target cells defective in the p53 pathway? J Virol 2001, 75:5443-5447.
9. Li H, Haviv YS, Derdeyn CA Lam J, Coolidge C, Hunter E, Curiel DT, Blackwell JL: Human immunodeficiency virus type I-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles. Hum Gene Ther 2001, 12:2155-2165.
10. Sarkar D, Su ZZ, Vozhilla N, Park ES, Randolph A, Valerie K, Fisher PB: Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Res 2005, 65:9056-9063.
11. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB: Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci U S A 2005, 102:14034-14039.
12. Gillet L, Dewals B, Farnir F, de Leval L, Vanderplasschen A: Bovine herpesvirus 4 induces apoptosis of human carcinoma cell lines in vitro and in vivo. Cancer Res 2005, 65:9463-9472.
13. Jeeninga RE, Van der Linden B, Jan B, Van den Berg H, Berkhout B: Construction of a minimal HIV-1 variant that selectively replicates in leukemic derived T-cell lines: towards a new virotherapy approach. Cancer Res 2005, 65:3347-3355.
14. Berkhout B, Verhoef K, van Wamel JLB, Back B: Genetic instability of live-attenuated HIV-1 vaccine strains. J Virol 1999, 73:1138-1145.
15. Birch MR, Learmont JC, Dyer WB, Deacon NJ, Zaunders JJ, Saksena N, Cunningham AL, Mills J, Sullivan JS: An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC). J Clin Virol 2001, 22:263-270.
16. Verhoef K, Marzio G, Hillen W, Bujard H, Berkhout B: Strict control of human immunodeficiency virus type I replication by a genetic switch: Tet for Tat. J Virol 2001, 75:979-987.
17. Berkhout B, Verhoef K, Marzio G, Klaver B, Vink M, Zhou X, Das AT: Conditional virus replication as an approach to a safe live attenuated human immunodeficiency virus vaccine. J Neurovirol 2002, 8 (Suppl 2):134-137.
18. Marzio G, Verhoef K, Vink M, Berkhout B: In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies. Proc Natl Acad Sci USA 2001, 98:6342-6347.
19. Verhoef K, Koper M, Berkhout B: Determination of the minimal amount of Tat activity required for human immunodeficiency virus type I replication. Virol 1997, 237:228-236.
20. Verhoef K, Berkhout B: A second-site mutation that restores replication of a Tat-defective human immunodeficiency virus. J Virol 1999, 73:2781-2789.
21. Das AT, Verhoef K, Berkhout B: A conditionally replicating virus as a novel approach toward an HIV vaccine. Methods Enzymol 2004, 388:359-379.
22. Marzio G, Vink M, Verhoef K, de Ronde A, Berkhout B: Efficient human immunodeficiency virus replication requires a fine-tuned level of transcription. J Virol 2002, 76:3084-3088.
23. Cullen BR: Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol 2006, 80:1067-1076.
24. Rhodes DI, Ashton L, Solomon A, Carr A, Cooper D, Kaldor J, Deacon N: Characterization of three nef-defective human immunodeficiency virus type I strains associated with long-term nonprogression. Australian Long-Term Nonprogressor Study Group. J Virol 2000, 74:10581-10588.
25. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, Lawson VA, Crowe S, Maerz A, Sonza S, Learmont J, Sullivan JS, Cunningham A, Dwyer D, Dowton D, Mills J: Genomic structure of an attenuated quasi species of HIV-1 from blood transfusion donor and recipients. Science 1995, 270:988-991.
26. Lum JJ, Cohen OJ, Nie Z, Weaver JG, Gomez TS, Yao XJ, Lynch D, Pilon AA, Hawley N, Kim JE, Chen Z, Montpetit M, Sanchez-Dardon J, Cohen EA, Badley AD: Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest 2003, 111:1547-1554.
27. James CO, Huang MB, Khan M, Garcia-Barrio,M, Powell MD, Bond VC: Extracellular Nef protein targets CD4+ T cells for apoptosis by interacting with CXCR4 surface receptors. J Virol 2004, 78:3099-3109.
28. de Ronde A, Klaver B, Keulen W, Smit L, Goudsmit J: Natural HIV-1 NEF accelerates virus replication in primary human lymphocytes. Virol 1992, 188:391-395.
29. Somasundaran M, Sharkey M, Brichacek B, Luzuriaga K, Emerman M, Sullivan JL, Stevenson M: Evidence for a cytopathogenicity determinant in HIV-1 Vpr. Proc Natl Acad Sci U S A 2002, 99:9503-9508.
30. Sakai K, Dimas J, Lenardo MJ: The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc Natl Acad Sci U S A 2006, 103:3369-3374.
31. Westerhout EM, Vink M, Haasnoot PC, Das AT, Berkhout B: A conditionally replicating HIV-based vector that stably expresses an antiviral shRNA against HIV-1 replication. Mol Ther 2006, 14:268-275.
32. Berkhout B, Jeang KT: Trans activation of human immunodeficiency virus type I is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis. J Virol 1989, 63:5501-5504.
33. Berkhout B, Klaver B: In vivo selection of randomly mutated retroviral genomes. Nucleic Acids Res 1993, 21:5020-5024.
34. Feng S, Holland EC: HIV-1 tat trans-activation requires the loop sequence within tar. Nature 1988, 334:165-167.
35. Klaver B, Berkhout B: Evolution of a disrupted TAR RNA hairpin structure in the HIV-1 virus. EMBO J 1994,13:2650-2659.
36. Chattopadhyay SK, Morse HCIII, Makino M, Ruscetti SK, Hartley JW: Defective virus is associated with induction of murine retrovirus-induced immunodeficiency syndrome. Proc Natl Acad Sci USA 1989, 86:3862-3866.
37. Desfosses Y, Solis M, Sun Q, Grandvaux N, Van Lint C, Burny A, Gatignol A, Wainberg MA, Lin R, Hiscott J: Regulation of human immunodeficiency virus type I gene expression by clade-specific tat proteins. J Virol 2005, 79:9180-9191.
38. Das AT, Zhou X, Vink M, Klaver B, Verhoef K, Marzio G, Berkhout B: Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J Biol Chem 2004, 279:18776-18782.
39. Gibbs JS, Regier DA, Desrosiers RC: Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses 1994, 10:343-350.
40. Auersperg N: Long-term cultivation of hypodiploid human tumor cells. J Nat Cancer Inst 1964, 32:135-163.
41. Das AT, Klaver B, Berkhout B: A hairpin structure in the R region of the Human Immunodeficiency Virus type I RNA genome is instrumental in polyadenylation site selection. J Virol 1999, 73:81-91.
42. Smith SD, Shatsky M, Cohen PS, Warnke R, Link MP, Glader BE: Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res 1984, 44:5657-5660.
43. Melkonyan H, Sorg C, Klempt M: Electroporation efficiency in mammalian cells is increased by dimethyl sulfoxide (DMSO). Nucleic Acids Res 1996, 24:4356-4357.
44. Jeeninga RE, Keulen W, Boucher C, Sanders RW, Berkhout B: Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect. Virol 2001, 283:294-305.